{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:04:48Z","timestamp":1756339488798,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>We report a case of a man in his 70s who developed haemoptysis 3\u2009days after commencing sildenafil. Before postulating a potential connection between sildenafil use and haemoptysis, it is important to rule out potential other causative factors and comorbidities. The patient suffers from multiple medical conditions and takes various medications. On examination, no abnormalities were discovered. There were no recent significant changes in his bloodwork. Cessation of sildenafil coincided with spontaneous symptom resolution. Chest CT was performed, and no abnormalities were reported. Pseudohaemoptysis or malignancy may be the main differential diagnoses of haemoptysis in elderly patients with multiple comorbidities. Concurrent anticoagulation of the patient may predispose to haemoptysis and is likely to be of greater clinical concern.<\/jats:p>","DOI":"10.1136\/bcr-2023-258050","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:54:32Z","timestamp":1722257672000},"page":"e258050","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Transient haemoptysis after taking sildenafil"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9710-4835","authenticated-orcid":false,"given":"Suheyla","family":"Karaduman","sequence":"first","affiliation":[{"name":"Internal Medicine, St Mary's General Hospital, Passaic, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-4460","authenticated-orcid":false,"given":"Azmaeen","family":"Zarif","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge, Cambridge, UK"},{"name":"Gonville & Caius College, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alesia","family":"Talpeka","sequence":"additional","affiliation":[{"name":"Belarusian State Medical University, Minsk, Belarus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Haseeb","sequence":"additional","affiliation":[{"name":"Allama Iqbal Unani Medical College and Hospital Garden, Uttar Pradesh, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"2025082707580902000_17.7.e258050.1","unstructured":"Pfizer . Viagra (Sildenafil citrate). U.S. Food and Drug Administration; 2014. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/20895s039s042lbl.pdf [Accessed 21 Aug 2023]."},{"key":"2025082707580902000_17.7.e258050.2","unstructured":"Pfizer . Revatio (Sildenafil). U.S. Food and Drug Administration; 2014. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021845s011,022473s004,0203109s002lbl.pdf [Accessed 21 Aug 2023]."},{"key":"2025082707580902000_17.7.e258050.3","unstructured":"Pfizer . Viagra (Sildenafil citrate). U.S. Food and Drug Administration; 2010. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020895s033lbl.pdf [Accessed 22 Aug 2023]."},{"key":"2025082707580902000_17.7.e258050.4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00380-020-01604-1","article-title":"Pulmonary vasodilators can lead to various complications in pulmonary \"arterial\" hypertension associated with congenital heart disease","volume":"35","author":"Chida-Nagai","year":"2020","journal-title":"Heart Vessels"},{"key":"2025082707580902000_17.7.e258050.5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4037\/ajcc1998.7.2.131","article-title":"Nitric oxide and regulation of vascular tone: pharmacological and physiological considerations","volume":"7","author":"McHugh","year":"1998","journal-title":"Am J Crit Care"},{"key":"2025082707580902000_17.7.e258050.6","first-page":"144","article-title":"Haemoptysis: evaluation and management","volume":"105","author":"O\u2019Gurek","year":"2022","journal-title":"Am Fam Physician"},{"key":"2025082707580902000_17.7.e258050.7","doi-asserted-by":"crossref","first-page":"W19","DOI":"10.1097\/RTI.0000000000000084","article-title":"ACR appropriateness criteria haemoptysis","volume":"29","author":"Ketai","year":"2014","journal-title":"J Thorac Imaging"},{"key":"2025082707580902000_17.7.e258050.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.1070","article-title":"Diffuse alveolar hemorrhage resulting from rivaroxaban use: a rare complication in a patient without predisposing conditions","volume":"160","author":"Rovnan","year":"2021","journal-title":"Chest"},{"key":"2025082707580902000_17.7.e258050.9","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12075"},{"key":"2025082707580902000_17.7.e258050.10","unstructured":"Janssen . Xarelto (Rivaroxaban). U.S. Food and Drug Administration; 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf [Accessed 22 Aug 2023]."},{"key":"2025082707580902000_17.7.e258050.11","first-page":"216","article-title":"Diffuse alveolar hemorrhage associated with Rivaroxaban therapy. J-Stage","volume":"40","author":"Ito","year":"2018","journal-title":"J Jpn Soc Respir Endosc"},{"key":"2025082707580902000_17.7.e258050.12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1745-7262.2006.00194.x","article-title":"Haemoptysis developing soon after use of sildenafil: an observation on two cases","volume":"8","author":"Yuncu","year":"2006","journal-title":"Asian J Androl"},{"key":"2025082707580902000_17.7.e258050.13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hrtlng.2012.02.003","article-title":"Pulmonary hemorrhage after the use of sildenafil","volume":"41","author":"Pereira e Silva","year":"2012","journal-title":"Heart Lung"},{"key":"2025082707580902000_17.7.e258050.14","first-page":"119","article-title":"Recurrent Haemoptysis following sildenafil administration","volume":"51","author":"Dixit","year":"2009","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"2025082707580902000_17.7.e258050.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2023.07.3017","article-title":"An uncommon case of Haemoptysis in a 62-year-old male","volume":"164","author":"Elkhawas","year":"2023","journal-title":"Chest"},{"key":"2025082707580902000_17.7.e258050.16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4266\/kjccm.2015.30.1.31","article-title":"Diffuse alveolar hemorrhage confirmed by bronchoalveolar lavage in a patient with haemoptysis after sildenafil use for erectile dysfunction","volume":"30","author":"Moon","year":"2015","journal-title":"Korean J Crit Care Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-258050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:58:18Z","timestamp":1756306698000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-258050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bcr-2023-258050"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-258050","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}